NCT05983627View on ClinicalTrials.gov

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Respiratory Distress Syndrome
Interventions
BIOLOGICAL

Human Umbilical Cord Mesenchymal Stem Cells

The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.

All Listed Sponsors
lead

Asia Cell Therapeutics (Shanghai) Co., Ltd.

INDUSTRY

NCT05983627 - Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter